Varenicline and Bupropion for Smoking Cessation

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Smoking

In brief

This study provides an opportunity to combine varenicline and bupropion SR and capitalize on the potential additive benefit. The investigators hypothesize that this will further increase long-term (≥ 6 months) smoking abstinence rates.

Key facts

Study ID

NCT00935818

Run by

Mayo Clinic

People needed

506

Starts

2009-09-01

Expected to finish

2013-04-01

Last updated by the study team

2014-05-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subject is at least 18 years of age;
• Subject has provide written informed consent;
• Subject is smoking greater than or equal to 10 cigarettes per day for at least 6 months;
• Subject is able to complete all study visits 4) Subject is in good health as determined by the investigator 5) Subject has the ability to participate fully in all aspects of the study and keep scheduled appointments 6) Subject is motivated to stop smoking.

You may not qualify if…

• Female and were pregnant, lactating or likely to become pregnant during the trial and not able nor willing to use contraception or had:
• an unstable medical condition;
• another household member participating in the study;
• bupropion or varenicline allergy;
• current use (previous 30 days) of a tobacco dependence treatment and unable or unwilling to discontinue use;
• an unstable medical condition or unstable angina, myocardial infarction, or coronary angioplasty (past 3 months) or an untreated cardiac dysrhythmia;
• a history of renal failure or were on renal dialysis;
• a history of seizures;
• as defined by the C-SSRS (Columbia-Suicide Severity Rating Scale), current non-specific suicidal thoughts or lifetime history of a suicidal attempt (defined as "potentially self-injurious act committed with at least some wish to die, as a result of act");
• a history of closed head trauma associated with > 30 minutes of loss of consciousness, amnesia, skull fracture, subdural hematoma, or brain contusion;
• a history or psychosis, bipolar disorder, bulimia or anorexia nervosa;
• current moderate or severe depression as assessed by a score of ≥ 20 on the Beck Depression Inventory, Second Edition (BDI-II) 10;
• active substance abuse other than nicotine;
• current (past 14 days) use of an antipsychotic, monoamine oxidase inhibitors, or drugs known to interact with bupropion SR;
• a recent dose change of their antidepressant (within last 3 months);
• untreated hypertension or baseline systolic blood pressure > 180 or diastolic > 100;
• current treatment with another investigational drug for tobacco dependence (previous 30 days); or
• current use of bupropion or varenicline (previous 30 days).

Where it is running

• University Of Minnesota — Minneapolis, Minnesota, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Franciscan Skemp Hospital — La Crosse, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.